Recent News

WCLC 2018: Video-Assisted Thoracoscopic Surgery vs. Thoracotomy for Early-Stage Disease

FDA Grants Priority Review to Pembrolizumab as First-Line Treatment in NSCLC Subset

Can m-TORC1/2 Inhibitor Added to Chemotherapy Improve Outcomes in Lung Cancer?

New Therapeutic Strategy for KRAS-Dependent Lung Cancer

RET Inhibitor for NSCLC Granted Breakthrough Therapy Designation by FDA

Can Liquid Biopsy Predict Benefit From Immunotherapy in Lung Cancer?

Building MRI Videos for Planning Lung Cancer Radiotherapy

FDA Approves EGFR-Mutation Test for Use With Gefitinib in NSCLC

Study Reports Upside to Adverse Events With Nivolumab Treatment of NSCLC

FDA Approves Pembrolizumab Plus Chemotherapy as First-Line Treatment of NSCLC

Are Lung Cancer Screening Guidelines Adequate for High-Risk Minorities?

IASLC Unveils Comprehensive Assessment of Liquid Biopsy for Patients With NSCLC

Can Simplified Screening Methods Accurately Indicate Pathology in NSCLC?

World Lung Cancer Day Commemorated by International Respiratory Societies

Novel Vaccine for Lung Cancer Moves Into Phase I Clinical Trial

Is Physical Inactivity Linked to Lung Cancer Risk?

Alectinib Versus Crizotinib in Advanced ALK-Positive Lung Cancer

Who Has Higher Incidence of Lung Cancer in United States: Young Women or Young Men?

Study Results Support Survival Benefit of Atezolizumab-Based Therapy in NSCLC

FDA Expands Approval of Pembrolizumab for First-Line Treatment of NSCLC

Long Noncoding RNAs as Potential Biomarkers in Non–Small Cell Lung Cancer

FDA Accepts Application for First-Line Combination Immunotherapy in Subgroup With NSCLC

ASCO 2018: Safety Analysis of First-Line Nivolumab Plus Ipilimumab for Advanced NSCLC

Projected Lung Cancer Rates in Patients Living With HIV

Combined Effects of FLT3 Ligand and Stereotactic Radiotherapy In Lung Cancer

ASCO 2018: Potential New Standard of Care in Pembrolizumab Combination for Advanced Squamous NSCLC

Expanded Indication for Pemetrexed in Combination Treatment of Metastatic NSCLC

ASCO 2018: Final Overall Survival Results With Dacomitinib vs. Gefitinib in NSCLC

ASCO 2018: Can Genome-Wide Sequencing Assays Detect Early-Stage Lung Cancer?

ASCO 2018: Addition of Immunotherapy to Chemotherapy for Advanced Squamous NSCLC

ASCO 2018: First-Line Pembrolizumab Versus Chemotherapy in Advanced Lung Cancer

Can Radiotherapy Improve Survival in Patients With Metastatic NSCLC?

FDA Accepts New Drug Application for Larotrectinib in Treatment of Certain Solid Tumors

Analysis of Circulating Tumor Cells in Patients With Early Lung Cancer

Second-Line TKI for Leptomeningeal Metastases in Lung Cancer

Atezolizumab Plus Bevacizumab and Chemotherapy in Nonsquamous Lung Cancer

Effect of Cardiac Doses on Survival in NSCLC After Accelerated Radiotherapy

ASCO 2018 Preview: Economic Impact of Genomic Testing Options in Metastatic NSCLC

ASCO 2018 Preview: Low Rates of Lung Cancer Screening Across the United States

Prophylactic Cranial Irradiation and Quality of Life for Patients With NSCLC

Response to Lorlatinib in ALK-Positive Lung Cancer

Pemetrexed Exposure and Adverse Events in NSCLC

FDA Grants Priority Review to Atezolizumab Combination for Metastatic Lung Cancer

AATS 2018: Staging-to-Surgery Time Interval in Stage I NSCLC

FDA Grants Priority Review to Supplemental Biologics License Application for Pembrolizumab in NSCLC

AACR 2018: Tumor Mutational Burden as Biomarker of Response to Immunotherapy in Lung Cancer

ESTRO 37: Concurrent Chemoradiotherapy in Older Patients With Lung Cancer

ELCC 2018: Patient-Reported Outcomes With Durvalumab From PACIFIC Trial

AACR 2018: Nivolumab/Ipilimumab Combination as First-Line Treatment in Advanced NSCLC

ELCC 2018: First-Line Osimertinib in Lung Cancer With Sensitizing EGFR Mutation

AACR 2018: Neoadjuvant Nivolumab for Resectable Lung Cancer

FDA Grants Approval to Osimertinib as First-Line Therapy for Metastatic NSCLC With EGFR Mutations

NCCN Annual Conference 2018: Debut of New Guidelines on Immunotherapy-Related Toxicity

ELCC 2018: Patient-Reported Outcomes With Alectinib Versus Crizotinib in ALK-Positive Lung Cancer

AACR 2018: First-Line Pembrolizumab Plus Chemotherapy for Metastatic Lung Cancer

ELCC 2018: Updated Survival Results With Atezolizumab in the POPLAR Trial

NCCN Annual Conference 2018: Updated Guidelines for NSCLC

FDA Accepts New Drug Application for Dacomitinib to Treat NSCLC With EGFR Mutations

Novel Tissue-Imaging Technology Used for Predicting Recurrence of Lung Cancer